Want to see HK:2696 full AI Analyst Report?
2696 Stock Chart & Stats
HK$66.75
HK$0.05(0.21%)
At close: 4:00 PM EST
HK$66.75
HK$0.05(0.21%)
Day’s Range― - ―
52-Week RangeHK$50.25 - HK$87.10
Previous CloseN/A
Volume849.10K
Average Volume (3M)1.15M
Market Cap
HK$31.98B
Enterprise ValueHK$38.71K
Total Cash (Recent Filing)HK$956.02M
Total Debt (Recent Filing)HK$3.95B
Price to Earnings (P/E)31.5
Beta0.59
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding347,862,400
10 Day Avg. Volume847,638
30 Day Avg. Volume1,150,974
Financial Highlights & Ratios
PEG Ratio-13.16
Price to Book (P/B)7.06
Price to Sales (P/S)4.20
P/FCF Ratio32.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$97.02Price Target Upside45.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Profitability And GrowthPositive net income across 2023–2025, paired with 69–74% gross margins, indicates the commercial portfolio has moved beyond early-stage development economics. This provides a stronger base for funding pipeline activity and absorbing normal operating investment over the next several quarters.
Improving Balance SheetDebt-to-equity fell to about 0.91 in 2025 from above 2.2 in 2022, while equity strengthened and returns on equity were solid. This improves financial resilience and reduces balance-sheet pressure, although it does not eliminate biotech execution sensitivity.
Positive Operating Cash GenerationOperating cash flow was positive in every year from 2021–2025, and free cash flow was positive in 2023–2025. That recurring cash generation gives Henlius internally generated funding for operations and commercialization, rather than relying solely on external capital.
Bears Say
2025 Margin CompressionAlthough profitability remains positive, 2025 net and operating profitability declined versus 2024. Margin compression can reduce earnings leverage as revenue expands and may constrain the cash available for pipeline development or other strategic investment.
Meaningful And Volatile LeverageDespite improvement, leverage remains meaningful for a biotech company and has been historically volatile. That leaves Henlius more exposed to execution setbacks because weaker-than-expected development or commercialization outcomes could increase balance-sheet sensitivity.
Uneven Free Cash FlowFree cash flow fell about 8% year over year in 2025, while historical cash conversion was uneven and FCF was negative in 2020–2022. This volatility points to continuing investment demands and makes internally funded growth less predictable.
Shanghai Henlius Biotech, Inc. Class H News
2696 FAQ
What was Shanghai Henlius Biotech, Inc. Class H’s price range in the past 12 months?
Shanghai Henlius Biotech, Inc. Class H lowest stock price was HK$50.25 and its highest was HK$87.10 in the past 12 months.
What is Shanghai Henlius Biotech, Inc. Class H’s market cap?
Shanghai Henlius Biotech, Inc. Class H’s market cap is HK$31.98B.
When is Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Shanghai Henlius Biotech, Inc. Class H’s earnings last quarter?
Currently, no data Available
Is Shanghai Henlius Biotech, Inc. Class H overvalued?
According to Wall Street analysts Shanghai Henlius Biotech, Inc. Class H’s price is currently Undervalued.
Does Shanghai Henlius Biotech, Inc. Class H pay dividends?
Shanghai Henlius Biotech, Inc. Class H does not currently pay dividends.
What is Shanghai Henlius Biotech, Inc. Class H’s EPS estimate?
Shanghai Henlius Biotech, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Henlius Biotech, Inc. Class H have?
Shanghai Henlius Biotech, Inc. Class H has 347,862,400 shares outstanding.
What happened to Shanghai Henlius Biotech, Inc. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shanghai Henlius Biotech, Inc. Class H?
Currently, no hedge funds are holding shares in HK:2696
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Henlius Biotech, Inc. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$97.02 (45.35% Upside)
HK$97.02 (45.35% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
2696 Stock 12 Month Forecast
Average Price Target
HK$97.02
▲(45.35% Upside)
Technical Analysis
Innovent Biologics
―
3SBio
―
Wuxi Biologics (Cayman)
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―